Related Experiment Video
Updated: May 15, 2026

Disposable Dosators Intended for Dry Powder Delivery to Mice
Published on: August 18, 2023
Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape,
Asha R Srinivasan1, Sunday A Shoyele
1Department of Pharmaceutical Sciences, School of Pharmacy, Thomas Jefferson University, 130 South 9th Street, Edison Building, Suite 1540, Philadelphia, Pennsylvania 19107, USA.
Abstract:
The ability to produce submicron particles of monoclonal antibodies of different sizes and shapes would enhance their application to pulmonary delivery. Although non-ionic surfactants are widely used as stabilizers in protein formulations, we hypothesized that non-ionic surfactants will affect the shape and size of submicron IgG particles manufactured through precipitation. Submicron particles of IgG1 were produced by a precipitation process which explores the fact that proteins have minimum solubility but maximum precipitation at the isoelectric point. Non-ionic surfactants were used for size and shape control, and as stabilizing agents. Aerosol performance of the antibody nanoparticles was assessed using Andersen Cascade Impactor. Spinhaler® and Handihaler® were used as model DPI devices. SEM micrographs revealed that the shape of the submicron particles was altered by varying the type of surfactant added to the precipitating medium. Particle size as measured by dynamic light scattering was also varied based on the type and concentration of the surfactant. The surfactants were able to stabilize the IgG during the precipitation process. Polyhedral, sponge-like, and spherical nanoparticles demonstrated improved aerosolization properties compared to irregularly shaped (>20 μm) unprocessed particles. Stable antibody submicron particles of different shapes and sizes were prepared. Careful control of the shape of such particles is critical to ensuring optimized lung delivery by dry powder inhalation.
Related Concept Videos
Micelles
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Surface Active Agents
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

